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Background: Early-onset hearing loss is mostly of genetic origin. The complexity of the hearing process is reflected
by its extensive genetic heterogeneity, with probably many causative genes remaining to be identified. Here, we
aimed at identifying the genetic basis for autosomal dominant non-syndromic hearing loss (ADNSHL) in a large
German family.
Methods: A panel of 66 known deafness genes was analyzed for mutations by next-generation sequencing
(NGS) in the index patient. We then conducted genome-wide linkage analysis, and whole-exome sequencing
was carried out with samples of two patients. Expression of Osbpl2 in the mouse cochlea was determined by
immunohistochemistry. Because Osbpl2 has been proposed as a target of miR-96, we investigated homozygous
Mir96 mutant mice for its upregulation.
Results: Onset of hearing loss in the investigated ADNSHL family is in childhood, initially affecting the high frequencies
and progressing to profound deafness in adulthood. However, there is considerable intrafamilial variability. We
mapped a novel ADNSHL locus, DFNA67, to chromosome 20q13.2-q13.33, and subsequently identified a co-segregating
heterozygous frameshift mutation, c.141_142delTG (p.Arg50Alafs*103), in OSBPL2, encoding a protein known to interact
with the DFNA1 protein, DIAPH1. In mice, Osbpl2 was prominently expressed in stereocilia of cochlear outer and inner
hair cells. We found no significant Osbpl2 upregulation at the mRNA level in homozygous Mir96 mutant mice.
Conclusion: The function of OSBPL2 in the hearing process remains to be determined. Our study and the recent
description of another frameshift mutation in a Chinese ADNSHL family identify OSBPL2 as a novel gene for
progressive deafness.
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Hearing impairment is the most common sensory dis-
order, affecting approximately 1/500 newborns. In devel-
oped countries, most cases are of genetic origin, and
there is extensive allelic and non-allelic heterogeneity.
In 70% of hearing-impaired neonates, the sensory def-
icit is non-syndromic (non-syndromic hearing loss,* Correspondence: hanno.bolz@bioscientia.de
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dominantly-inherited forms (ADNSHL) and typically
display postlingual progressive hearing impairment.
Sixty-five ADNSHL loci have been officially designated,
and 30 causative genes have been reported [1-3]. Because
of the extensive genetic heterogeneity of hearing impair-
ment, the identification of the causative mutation in single
patients has been the exception until recently. With the
advent of next-generation sequencing (NGS), deafness
genes have become accessible to comprehensive genetic
analysis and routine genetic testing by targeted NGS of
“gene panels” [4].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Patients
Samples of the German family reported herein (Figure 1)
were obtained with written informed consent. Clinical
investigations were conducted according to the Declar-
ation of Helsinki, and the study was approved by the
institutional review board of the Ethics Committee of
the University Hospital of Cologne. The affected subjects
underwent detailed audiological evaluations (e.g., pure
tone audiometric air conduction, bone conduction, speech
reception threshold, otoacoustic emissions, and imped-
ance audiometry, phoneme discrimination), except IV:12
who reports intermittent hearing impairment (related
to stress). Following the recommendations of the EU
HEAR project [5], hearing loss was classified as mild
(20 – 40 dB), moderate (41 – 70 dB), severe (71 – 95 dB),
or profound (>95 dB). This classification, however, was
difficult in some cases, because at least two patients
(V:2, V:3) had near normal hearing in the 250 – 1000 Hz
region, but a loss of about 70 – 90 dB in the higher
frequencies.
GJB2 analysis and targeted NGS of a deafness gene panel
The GJB2 gene was directly sequenced in the index
patient, IV:10. His sample was then subjected to NGS
for 66 genes (1,259 coding exons) that have been associ-
ated with NSHL and selected forms of SHL on a MiSeq
system (Illumina) as described previously [6]. In brief,
sheared DNA was ligated to bar-coded adaptors for
multiplexing. Exons were targeted by an in-solution
customized sequence capture library (NimbleGen). Amp-
lified enriched DNA was directly subjected to NGS
(MiSeq). Reads were mapped against the hg19 human
reference genome using BWA [7] and processed withFigure 1 Pedigree and genotypes of the DFNA67 family. M, OSBPL2 mu
subjected to genome-wide SNP genotyping for linkage analysis. Green starSAMtools [8], Picard (http://broadinstitute.github.io/picard/)
and GATK [9]. Variants were filtered against dbNSFP v2.0
[10], dbSNP v137, the Human Gene Mutation Database
(HGMD® Professional 2013.2) [11] and our in-house data-
base. The cutoff for the maximum minor allele frequency
(MAF) was set to 1% [12]. Nonsense, frameshift and
canonical splice site variants were regarded likely patho-
genic. SNVs were assessed using SIFT [13], Mutation
Taster [14], PolyPhen-2 [15], AlignGVGD [16,17], Pmut
[18], NNSPLICE v0.9 [19] and NetGene2 [20,21]. SeqPilot
SeqNext module (v4.0.1, JSI medical systems) was used
for visualization and final assessment of SNVs.Linkage analysis and locus designation
DNA samples from seven affected and six unaffected
members of the family (Figure 1) were genotyped using
the Affymetrix GeneChip Human Mapping 10 K SNP
array Xba142. The gender was verified by counting het-
erozygous single nucleotide polymorphisms (SNPs) on
the X chromosome. Relationship errors were evaluated
with the help of the program Graphical Representation of
Relationships [22]. Linkage analysis was performed assum-
ing autosomal dominant inheritance, full penetrance,
and a disease gene frequency of 0.0001. Multipoint LOD
scores were calculated using the program ALLEGRO [23].
Haplotypes were reconstructed with ALLEGRO and
presented graphically with HaploPainter [24]. All data
handling was performed using the graphical user interface
ALOHOMORA [25].
Following the identification of the causative mutation in
OSBPL2, DFNA67 was assigned as a novel locus designa-
tion for ADNSHL by the Human Gene Nomenclature
Committee, HGNC.tation; WT, wildtype. Blue stars, individuals whose samples were
s, individuals whose samples were subjected to WES.
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Samples of two affected family members, IV:10 and V:3,
were subjected to whole-exome sequencing (WES).
DNA (1 μg) was fragmented using sonication technology
(Covaris). Fragments were enriched using the SeqCap
EZ Human Exome Library v2.0 kit (Roche NimbleGen)
and subsequently sequenced on an Illumina HiSeq 2000
sequencing instrument using a paired-end 2 × 100-bp
protocol. This generated 6.1 and 8.2 Gb of mapped se-
quences with a mean coverage of 80-fold and 101-fold, a
30-fold coverage of 89% and 89% of the target sequences
and a 10-fold coverage of 96% and 95% of the target se-
quences. For data analysis, the Varbank pipeline (v.2.3)
and filter interface was used (https://varbank.ccg.uni-
koeln.de). Primary data were filtered according to signal
purity by Illumina Real-Time Analysis (RTA) software
(v1.8). Subsequently, the reads were mapped to the hu-
man genome reference build hg19 using the bwa-aln
alignment algorithm. GATK v1.6 [9] was used to mark
duplicated reads, perform local realignment around
short insertions and deletions, recalibrate the base qual-
ity scores, and call SNPs and short indels. Scripts devel-
oped in-house at the CCG were applied to variants
predicted to result in protein changes, variants affecting
donor and acceptor splice sites, and those overlapping
with known variants. Acceptor and donor splice site mu-
tations were analyzed with a maximum-entropy model
and filtered for their putative effect on splicing. In particu-
lar, we focused on the linkage regions (chr12:49,329,157-
52,752,362 and chr20:52,882,032-61,366,354; hg19) and
filtered for high-quality (>15-fold coverage; quality > 25;
VQSR > -2), and for rare (MAF <0.005) and heterozygous
variants. Several genome-wide databases (dbSNP Build
135, 1000 Genomes Project database build 20110521 [26]
and the public Exome Variant Server, NHLBI, Seattle,
build ESP6500 [27]) were checked for the presence of the
identified variants. To exclude pipeline-related artifacts
(MAF <0.005), we also filtered against an in-house data-
base containing variants from 511 exomes of individuals
with epilepsy. Finally, we filtered for variants present in
both patients. Verification of sequence variants and segre-
gation analyses were carried out by Sanger sequencing.
Sequence data for OSBPL2 (MIM 606731) were compared
to the reference sequence NM_144498.2.
RT-PCR from cochlear tissue
mRNA from mouse postnatal day 19 (P19) and rat P17
cochleae was isolated as described earlier [28]. A 298 bp
fragment of Osbpl2 was amplified using the following
primer sequences: 5′-CCAACTCTGCTCAGATGTACA
AC-3′ (forward) and 5′-GCTGTACGCCGGCCATTAC
TTTGA-3′ (reverse). PCR was performed with PuRe-
TaqTM Ready-To-GoTM PCR beads (GE Healthcare).
The amplification conditions consisted of an initialdenaturation phase of 94°C for 4 min, 35 cycles of 30 s
denaturation (94°C), 30 s annealing (58°C), 30 s extension
(72°C), and a final extension phase of 5 min at 72°C. The
PCR products were analyzed on ethidium bromide agar-
ose gels. Fragments were extracted using QIAquick Gel
Extraction Kit (Qiagen), cloned and sequenced.
Tissue preparation and immunohistochemistry
Cochleae from adult mice (aged between P20 and six
months) were used to prepare cryosections for immuno-
fluorescence microscopy. For immunohistochemistry on
cryosections, the temporal bone of mature mice was dis-
sected on ice and immediately fixed using Zamboni’s
fixative [29] containing picric acid by infusion through
the round and oval window and incubated for 15 min on
ice, followed by rinsing with phosphate-buffered saline
(PBS) and decalcification in rapid bone decalcifier
(Eurobio, Fisher-Scientific). After injection of 25% su-
crose in PBS, pH 7.4, cochleae were embedded in O.C.T.
compound (Miles Laboratories, Elkhart, IN). Tissues
were then cryosectioned at 10 μm thickness, mounted
on SuperFrost*/plus microscope slides, dried for 1 h and
stored at -20°C before use. Cryosections were thawed and
permeabilized with 0.1% Triton X-100 (Sigma Aldrich) for
3 min at room temperature, blocked with 1% BSA in PBS,
and incubated with primary antibody in 0.5% BSA in PBS
overnight at +4°C. For double labeling studies, specimens
were simultaneously incubated with both antibodies for
identical time periods. As primary antibodies we used:
anti-ORP-2 (OSBPL2) antibody (goat, Santa Cruz Biotech-
nology, Inc., sc-66570, dilution 1:50), anti-prestin antibody
(rabbit [30], dilution 1:5000), and anti-otoferlin antibody
(rabbit [31], dilution 1:10000). Primary antibodies were
detected with Cy3- (Jackson Immunoresearch Laborator-
ies) and Alexa488- (Invitrogen, Life Technologies GmbH)
conjugated secondary antibodies. Sections embedded with
Vectashield mounting medium containing nuclear marker
DAPI (Vector Laboratories). Sections were viewed using
an Olympus BX61 microscope equipped with motorized
z-axis and epifluorescence illumination. To increase dis-
play resolution, cochlear slices were imaged over a dis-
tance of several micrometers (30 × 0,27 μm, ~8 μm) in an
image stack along the z-axis (z-stack), followed by 3-
dimensional deconvolution using cellSens Dimension
module with the advanced maximum likelihood estima-
tion algorithm (ADVMLE; OSIS). Images were acquired
using a CCD camera and analyzed with cellSens software
(Olympus Soft Imaging Solutions, OSIS). Images were
processed with Photoshop.
Comparison of Osbpl2 mRNA levels between wildtype and
homozygous Mir96 mutant diminuendo (Mir96Dmdo) mice
Organ of Corti dissection, RNA extraction and cDNA
creation were carried out as described previously [32].
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Mm01318747_g1, Jag1: Mm01270190_m1, Osbpl2: Mm01
210488_m1). Hprt1 was used as an internal control, and
Jag1, which is expressed in supporting cells [32-34], was
used to control for the quantity of sensory tissue present.
Pairs were only used when Jag1 levels did not differ sig-
nificantly between wildtype and homozygote littermates
(p > 0.05). Three animals were genotyped and at least
three technical replicates were performed on each pair.
The reaction was run on a CFX Connect machine using
Bio-Rad SsoFast and SsoAdvanced Master mixes (Bio-Rad
Laboratories, cat. nos. 1725232, 1725281).
Results
Clinical characterization of DFNA67 patients
In most affected family members, bilateral sensorineural
non-syndromic hearing loss was first noted in the early
second decade of life and affected initially the high fre-
quencies. However, the age of onset varied between 10
(patients IV:7, V:6) and 30 years of age (III:9). Real onset
may have been earlier in many cases: Retrospectively,
the parents of patient V:3 assume that hearing was
already impaired around the age of 2 years. Progression
of hearing loss was also widely variable. It was mild in
younger individuals but severe to profound at later
stages (Figure 2) and required cochlear implantation be-
tween 27 and 50 years of age in five family members. On
the mild end of the spectrum, patient IV:10 noted onset
of hearing loss at 22 years of age and started using hear-
ing aids at 34 years. No audiological data were available
for IV:12, a 39-years old carrier of the OSBPL2 mutation,
who does not use hearing aids but claims worse hearing
in stressful situations. III:7 and V:2 reported progression
of hearing loss in the course of pregnancy and birth of
children (see Table 1 for a summary of clinical data).
Vestibular symptoms were not reported.
Mapping of chromosomal candidate loci
Using ALLEGRO we identifed two genomic regions
with a maximum LOD score of 2.7. The obtained LOD
score was the maximum possible LOD score in this
family. We found linkage to a 3.4 Mb interval between
SNPs rs1316607 and rs725029 on chromosome 12
(49,329,157 – 52,752,362) and to a 8.4 Mb interval
between rs2065042 and rs720607 on chromosome 20
(52,882,032 – 61,366,354) (Figure 3 A).
Targeted NGS, WES and segregation analysis of the
candidate variants identified
No mutation was identified in GJB2 and in subsequent
targeted NGS of 66 known deafness genes. After stringent
filtering of WES data, only two heterozygous variants
remained that localized to the chromosome 12 candidate
region: The c.1516C>G (p.Arg506Gly) variant in SLC11A2has been annotated in dbSNP (rs199589052), but no MAF
is available. Biallelic mutations in SLC11A2 cause auto-
somal recessive hypochromic microcytic anemia with iron
overload but there is no mention of any hearing impair-
ment [35]. It is therefore unlikely that heterozygous
SLC11A2 mutations cause ADNSHL. A missense variant,
c.53G>A (p.Arg18His), was identified in CELA1 (chymo-
trypsin-like elastase family, member 1). Because of its
expression in skin tissue, CELA1 had been considered a
candidate for skin disease. However, a common frameshift
polymorphism questioned essentiality of this gene [36].
Moreover, the p.Arg18His variant has an MAF of 0.28%
which is not compatible with a mutation causing a rare
autosomal dominant disorder.
There were two heterozygous missense variants in
genes contained in the candidate region on chromosome
20: The variant c.1202G>C (p.Arg401Pro) in GTPBP5
affects an evolutionarily non-conserved residue and has
been annotated as a polymorphism, rs200118420, with
an MAF of 0.04%. A variant in DIDO1 (c.1738A>C; p.
Thr580Pro), also affects a non-conserved residue. Mutant
Dido -/- and +/- mice appeared grossly normal. With
time, some heterozygous mice showed abnormalities in
spleen, bone marrow, and peripheral blood, overlapping
with symptoms of myeloid dysplasia or myeloid prolifera-
tion [37]. Taken together, none of these three missense
variants appeared to be a promising candidate for the
ADNSHL-causing mutation.
A nonsense mutation, c.287C>G (p.Ser96*), was found
in both patients in SLC17A9, a gene directly adjacent
(61,583,999 – 61,599,949) to the telomeric boundary of
the chromosome 20 locus. According to the Exome Vari-
ant Server, the SLC17A9 nonsense variant has an MAF of
0.06%, and compatible with the gene’s localization just
outside the candidate locus, it was carried by three healthy
individuals of the family (II:5, III:10, IV:13). Moreover, p.
Ser96*SLC17A9 was also present in heterozygous state in
three samples of our in-house database: A patient with
epilepsy, a patient with amyotrophic lateral sclerosis and
the healthy mother of that patient. None of these three
individuals had hearing loss.
We identified only one truncating variant in a gene
contained in a mapped candidate region: Both patients
carried the frameshift mutation c.141_142delTG (p.
Arg50Alafs*103) in OSBPL2 (Figure 3B,C), a gene from
the chromosome 20 region. This variant has not been
annotated in any of the above databases, no allele fre-
quency is available, and it co-segregated perfectly with
hearing loss in the family.
Expression of Osbpl2 in the murine cochlea
We analyzed the expression of Osbpl2 at the transcrip-
tional level of post-hearing animals using RT-PCR with

















Figure 2 Exemplary audiograms of patients from the DFNA67 family. Hearing thresholds are shown for the more severely affected side.
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size (298 bp) was found in both mouse (Figure 3D, lane 2)
and rat cochlea (Figure 3D; lane3). Next, we analyzed
Osbpl2 expression in the organ of Corti of mice at the
protein level using anti-Osbpl2 antibody in combination
with either anti-prestin antibody used as an outer hair cell
(OHC) marker or anti-otoferlin antibody used as an inner
hair cell (IHC) marker. Osbpl2 was detected in stereocilia
of both OHCs (Figure 4A,B) and IHCs (Figure 4C,D). We
found no difference in expression of Osbpl2 between P20
and 6-month-old mice (not shown).Comparison of Osbpl2 mRNA levels between wildtype
and homozygous Mir96 mutant mice
No significant difference was observed between wildtype
and homozygote levels of Osbpl2 mRNA in the organ of
Corti (Additional file 1).
Discussion
Mutations in approximately 30 genes have been impli-
cated in ADNSHL (with variable evidence) [2]. The
respective gene products fall into many different cat-
egories and comprise ion channels and transporters,
Table 1 Summary of clinical data
Individual Age (ys.) Hearing loss Age of onset (ys.) Course OSBPL2
II:1 36 (†) no no sample
II:2 69 (†) not noted by any of the five children,
but nasal pronunciation
? ? no sample
II:5 93 (†) no wildtype
II:7 78 (†) no no sample
III:2 76 no wildtype
III:4 71 unilateral (untreated otitis media) wildtype
III:6 74 (†) no wildtype
III:7 71 yes 12 worse after birth of children,
stress; CI around 50 ys.
p.Arg50Alafs*103
III:8 67 no wildtype
III:9 61 yes 30 CI at 50 ys. p.Arg50Alafs*103
III:10 64 only temporary, episodes of acute
hearing loss
wildtype
IV:6 58 no wildtype
IV:7 50 yes 10 CI at 36 ys. p.Arg50Alafs*103
IV:8 50 no wildtype
IV:9 49 yes 12 CI at 39 ys. p.Arg50Alafs*103
IV:10 45 yes 22 hearing aids at 34 ys. p.Arg50Alafs*103
IV:11 44 no wildtype
IV:12 39 no data from investigations;
hearing worse under stress
? ? p.Arg50Alafs*103
IV:13 35 no; two healthy daughters no sample
V:2 28 yes 15 worsening after birth of children; CI at 27 ys. p.Arg50Alafs*103
V:3 26 yes 11 hearing aids at 12 ys. p.Arg50Alafs*103
V:4 15 no wildtype
V:5 16 no wildtype
V:6 20 yes 10 hearing aids at 15 ys. p.Arg50Alafs*103
V:7 17 no wildtype
VI:1 3 no (normal OAEs at 3 ys.) wildtype
VI:2 4 months no
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the cytoskeleton, adhesion complexes etc. [1].
Of the five heterozygous variants found in genes from
the mapped candidate regions on chromosomes 12 and
20 in our family, the OSBPL2 frameshift mutation repre-
sented a reasonable candidate for the ADNSHL-causing
mutation (see results section). OSBPL2 does not belong
to any of the above protein classes. It is part of a 12-
member, evolutionarily highly conserved family of lipid
binding/transfer proteins, the oxysterol binding proteins
(OSBPs) and related proteins (OSBPLs) that share the
characteristic OSBP signature, EQVSHHPP [38]. OSBPL
proteins play an important role in non-vesicular intracel-
lular transport of lipids, particularly oxysterol, a deriva-
tive of cholesterol. OSBPLs serve as sterol sensors and
transporters that modulate the lipid composition of cellorganelle membranes and assembly of protein complexes,
thereby impacting signaling, vesicle transport and lipid
metabolism [39].
Osbpl2 was among 132 mRNAs with 3′UTRs pre-
dicted to contain potential target sites for miR-96 [32], a
microRNA whose mutations cause progressive hearing
loss in mice and humans [32,40], but we found no up-
regulation of Osbpl2 in Mir96 mutant mice (diminu-
endo) (Additional file 1). However, besides its previously
reported expression in the mouse organ of Corti at the
onset of hearing [41], there are several lines of evi-
dence that OSBPL2 is the gene underlying ADNSHL
in the family described herein: The frameshift mutation
c.141_142delTG very likely represents a loss-of-function
allele causing OSBPL2 haploinsufficiency. It either results
in a truncated non-functional protein of 151 residues
OSBPL2: c.141_142delTG (p.Arg50Alafs*103) 
A
C
G       G       A       A       A       A      C        T G       G       G       G        A G         A





Figure 3 (See legend on next page.)
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Figure 3 Genetics of the German DFNA67 family. A Graphical view of the LOD score calculation of genome-wide SNP mapping. A 3.4 Mb
region on chromosome 12 and an 8.4 Mb region on chromosome 20 showed potential linkage with the phenotype. B Ideogram of chromosome
20 with the position of OSBPL2 indicated (red bar). Schematic representation of the mapped sequencing reads (forward strand) visualized with
the Integrative Genomics Viewer (IGV) for patient IV:10. The c.141_142delTG (p.Arg50Alafs*103) mutation in OSBPL2 was present in half of the reads
covering this region of the gene. C Electropherogram of a heterozygous carrier of the OSBPL2 mutation in exon 3 (deleted nucleotides are boxed).
The localization of the mutation is indicated in a scheme of the OSBPL2 gene. D RT-PCR demonstrates Osbpl2 expression at the transcriptional
level in mouse (lane 2) and rat (lane3) cochlea. Lane 1, no cDNA as negative control.
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acids (p.Arg50Alafs*103) or in an unstable mRNA under-
going nonsense-mediated decay. OSBPL2 interacts with
diaphanous homologue 1 (DIAPH1) [42], the gene mu-
tated in human ADNSHL type 1 (DFNA1) [43]. DIAPH1
is a Rho effector protein that regulates cytoskeletal dy-
namics by interacting with actin, microtubules and other
proteins associated with cytoskeleton function [44,45].
Mutations in DIAPH1 are thought to impair the structural
integrity of hair cells’ stereocilia, which strongly depends
on their actin cytoskeleton, and of the kinocilium, which
is built around a microtubular backbone. As is assumed
for DIAPH1, OSBPL2 could play a role for the mainten-
ance of hair cells’ cytoskeleton, which would be compat-
ible with the prominent presence of OSBPL2 protein at
stereocilia (Figure 4). OSBPL2 binds phosphatidylinositol
(3,4,5)-trisphosphate (PtdIns(3,4,5)P3) [46], a phospholipid
of the plasma membrane that is crucial for defining neur-
onal polarity [47,48], a possible hint that OSBPL2 could
be needed to establish and maintain polarity of hair cells.Figure 4 OSBPL2 expression in stereocilia of mouse cochlear inner an
cochlear outer hair cells (OHC) as demonstrated by co-immunostaining wit
the primary antibody no immunostaining can be seen, which demonstrate
also expressed in stereocilia of cochlear inner hair cells (IHC) as demonstrat
stained with DAPI (blue). Scale bars, 10 μm.It remains to be determined if the interaction of both
proteins is reflected by (at least partial) cellular co-
localization.
Of note, an OSBPL2 frameshift mutation in close
proximity to the nucleotide position affected by the
mutation reported herein has recently been described to
co-segregate with ADNSHL in a large Chinese family
[49]. Similar to the German DFNA67 family, age of on-
set was variable (5 to 32 years), and hearing loss was
progressive, ranging from mild to profound. This add-
itional DFNA67 family strongly supports the association
of OSBPL2 mutations with ADNSHL.
A truncating variant in a gene closely neighboring the
chromosome 20 candidate locus, a nonsense mutation in
SLC17A9, p.Ser96*, is unlikely to cause hearing loss
because it was present in healthy individuals of both our
family and our in-house database of 511 epilepsy
exomes, and in the general population. SLC17A9 en-
codes a vesicular nucleotide transporter [50], and het-
erozygous mutations in this gene have recently beend outer hair cells. A, B OSBPL2 (green) is expressed in stereocilia of
h anti-prestin antibody (red) of mature (P20) mice. Upon omission of
s the specificity of the OSBPL2 antibody (inset). C, D OSBPL2 (green) is
ed by co-immunostaining with anti-otoferlin antibody (red). Nuclei are
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keratosis, DSAP [51]. None of the 12 individuals from
our DFNA67 family who carried the p.Ser96*SLC17A9 mu-
tation had any skin abnormalities. In conclusion,
SLC17A9 is not only unrelated to hearing loss in this
family; its haploinsufficiency does not seem to cause
DSAP either. The manifestation of DSAP might thus
only result from missense mutations with a dominant-
negative effect. On the other hand, our data challenge
the assumption that SLC17A9 mutations cause DSAP,
and additional research seems necessary to verify the
postulated implication of SLC17A9 in skin disease.
Conclusions
The association of OSBPL2 mutations with ADNSHL in-
dicates a role of lipid metabolism in hair cell function,
defining another functional category of proteins involved
in hearing loss. However, further research is necessary to
clarify how OSBPL2 deficiency causes hearing loss.
Other members of the OSBPL family should be consid-
ered as potential candidates in future studies aimed at
the identification of novel deafness genes.
Additional file
Additional file 1: Comparison of Osbpl2 mRNA levels between
wildtype and homozygous Mir96 mutant diminuendo (Mir96Dmdo)
mice. Quantitative real-time PCR on cDNA generated from normalised
RNA from the organs of Corti of 4-day-old wildtype (blue) and diminuendo
homozygote (red) littermates [32]. Error bars represent standard deviation.
Quantities were normalised to Hprt1 levels. No significant difference was
observed (p = 0.083, Student’s t-test).
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